India, Aug. 22 -- Shares of Rhythm Pharmaceuticals Inc. (RYTM) have crossed the $100 mark, as the company gears up for a key regulatory decision that is due in December.
This commercial-stage biopharmaceutical company is focused on transforming the lives of patients living with rare neuroendocrine diseases. Its lead asset is IMCIVREE, a once-daily injection, indicated for the treatment of obesity and to help control hunger associated with Bardet-Biedl syndrome or biallelic POMC, PCSK1, or LEPR deficiency. The drug is approved in the U.S. and over 15 other countries.
The company is also pursuing label expansion for IMCIVREE in both the U.S. and Europe to include its use for treating conditions related to acquired hypothalamic obesity. The ...